News
![astrazeneca-sign](https://pharmaphorum.com/wp-content/uploads/2017/08/AstraZeneca-sign.jpg)
AstraZeneca’s respiratory biologic fails again in COPD
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.